All In MedTech

Device Trial Radar · NCT06690086

DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin Cancer

DERMaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin Cancer (DERM-SUCCESS)

Last checked: Nov 20, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,028

Actual

Start

Aug 17, 2020

Primary completion

Dec 9, 2021

Study completion Dec 9, 2021

Sponsor

Lead sponsor
DermaSensor, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Mayo Clinic
First posted
Nov 15, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the clinical validity of the proprietary DermaSensor Elastic Scattering Spectroscopy (ESS) device and classifier algorithm to support assessment of skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in the primary care setting.

Conditions

  • Skin Cancer

Interventions

  • Lesion biopsyProcedure

    Lesions enrolled in the study are biopsied to confirm histopathology

  • DermaSensor Device UseDevice

    Users are blinded to the DermaSensor Device result

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity of DermaSensor for Skin Lesions Suggestive of Melanoma, BCC, and/or SCCTime frame: Day 1
  2. Sensitivity + Specificity > 1 for Skin Lesions Suggestive of Melanoma, BCC, and/or SCCTime frame: Day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.